FREMONT, Calif.--(BUSINESS WIRE)--ARYx Therapeutics Inc. (NASDAQ:ARYX), a biopharmaceutical company, today announced it has commenced enrollment in a Phase 2/3 clinical trial comparing its oral anticoagulation therapy, ATI-5923, against the leading anticoagulant agent, warfarin. The purpose of the trial, named EmbraceAC, is to evaluate whether ATI-5923 is superior to warfarin in its ability to maintain patients within a target therapeutic range of the level of anticoagulation. Based upon recent interactions with the United States Food and Drug Administration (FDA), ARYx Therapeutics believes this trial could be positioned as one of the required registration studies for ATI-5923. Results will be announced at the end of the second quarter of 2009.
